Navigation Links
InNexus Biotechnology CEO to Present at BioContactQuebec 2008
Date:9/29/2008

-- Receives Recognition in Two Leading Industry Publications --

BRITISH COLUMBIA, Canada, Sept. 29 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces Jeff Morhet, CEO and Chairman, to present during BioContactQuebec 2008. The company also announces the featuring of Mr. Morhet in two leading publications, Genetic Engineering & Biotechnology News and The PharmaVoice List of Top 100 in Life Sciences.

During BioContactQuebec 2008, InNexus' CEO will present on Thursday, October 2nd at 2:30-3:00 PM EDT on the Salle Laval at the Chateau Frontenac, Quebec. The presentation will include a company overview and information about InNexus' unique business strategy, its DXL(TM) technology platform and upcoming company milestones. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the symposium.

Also announced, the most recent edition of Genetic Engineering & Biotechnology News features InNexus CEO Morhet in the article, Peptide Drugs Becoming More Prevalent, where he discusses the pharmaceutical industry and outlines InNexus' DXL(TM) antibody enhancement technology platform. http://www.genengnews.com/articles/chitem.aspx?aid=2580.

The company also announced Mr. Morhet has also been named to PharmaVOICE's list of the "100 Most Inspiring People in the Life Sciences", July/August Edition. The publication illustrates those individuals who think outside the box, pioneering new paths to success and inspire their colleagues in the industry. http://www.pharmavoice.com

About BioContactQuebec 2008

BioContactQuebec 2008 is a biopharmaceutical partnership symposium gathering over 1200 participants and more than 150 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, presenting in different sectors of activities (diagnostics, therapeutics and services) and disciplines such as cancer, immunology and inflammation.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in- house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
2. InNexus Biotechnology Strengthens Patent Team With New Leadership
3. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
6. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
7. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
8. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
9. New Report on 633 Biotechnology Medicines Under Development Released in Michigan
10. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
11. Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
Breaking Biology News(10 mins):